FD 895

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: FD 895
• 英文别名: (8E,12E,14E)-7-acetoxy-3,6,17-trihydroxy-21-methoxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide；[(4E)-7,10-dihydroxy-2-[(2E,4E)-7-hydroxy-7-[3-(3-methoxypentan-2-yl)oxiran-2-yl]-6-methylhepta-2,4-dien-2-yl]-3,7-dimethyl-12-oxo-1-oxacyclododec-4-en-6-yl] acetate
• 化学式: C₃₁H₅₀O₉
• 分子量: 566.733
• InChiKey: LDCZLUDGHYDTHV-FPZDJJGISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  40
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  135
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• Novel bioactive substance
  申请人：Mizui Yoshiharu

  公开号：US20060079572A1

  公开（公告）日：2006-04-13

  The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution of Streptomyces sp. Mer. 11107 or a variant thereof, a pharmacologically acceptable salt thereof or a hydrate of them, and a process for producing it.

  本发明提供了一种具有抗肿瘤活性的新型生物活性物质及其制备方法和医药用途。具体而言，本发明提供了一种12元环大环内酯化合物，其化学式如下，该化合物是从链霉菌属海洋菌株Mer.11107或其变体的培养液中获得的，是一种药理学上可接受的盐或水合物，以及其制备方法。
• NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES
  申请人：KOTAKE Yoshihiko

  公开号：US20080255146A1

  公开（公告）日：2008-10-16

  The present invention relates to a compound represented by the formula (I): (wherein, R 3 , R 6 , R 7 and R 21 are the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition and is useful as a therapeutic agent for treating solid cancer.

  本发明涉及一种由式(I)表示的化合物：（其中，R3、R6、R7和R21相同或不同，每个代表羟基等），其药学上可接受的盐或水合物。本发明的化合物(I)抑制血管生成，特别是在低氧条件下抑制VEGF的产生，并且可用作治疗实体癌的治疗剂。
• Novel physiologically active substances
  申请人：MERCIAN CORPORATION

  公开号：EP2266978A1

  公开（公告）日：2010-12-29

  The present invention relates to a compound represented by the formula (I): (wherein, R3, R6, R7 and R21 are the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition and is useful as a therapeutic agent for treating solid cancer.

  本发明涉及一种由式（I）代表的化合物：（其中，R3、R6、R7和R21彼此相同或不同，且各自代表羟基等）、其药理学上可接受的盐或它们的水合物。 本发明的化合物(I)可抑制血管生成，特别是在缺氧条件下抑制血管内皮生长因子的产生，可作为治疗实体癌的治疗剂。
• SPLICEOSOME MUTATIONS AND USES THEREOF
  申请人：EISAI R&D MANAGEMENT CO., LTD.

  公开号：US20200190593A1

  公开（公告）日：2020-06-18

  Spliceosome mutations are described herein, including mutations in the PHF5A and SF3B1 subunits. This application also describes detecting the presence and/or absence of mutations in the spliceosome, as well as methods of diagnosing responsiveness to splice modulator treatment, methods of treating neoplastic disorders, and methods of monitoring or altering the treatment based on mutation status.
• US7026352B1
  申请人：——

  公开号：US7026352B1

  公开（公告）日：2006-04-11